Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

MLA

Martini, G., et al. “Cetuximab as Third‐line Rechallenge plus Either Irinotecan or Avelumab Is an Effective Treatment in Metastatic Colorectal Cancer Patients with Baseline Plasma RAS/BRAF Wild‐type Circulating Tumor DNA: Individual Patient Data Pooled Analysis of CRICKET and CAVE Trials.” Cancer Medicine, vol. 12, no. 8, Apr. 2023, pp. 9392–400. EBSCOhost, https://doi.org/10.1002/cam4.5699.

APA

Martini, G., Ciardiello, D., Famiglietti, V., Rossini, D., Antoniotti, C., Troiani, T., Napolitano, S., Esposito, L., Latiano, T. P., Maiello, E., Del, R. M., Lonardi, S., Aprile, G., Santini, D., Masi, G., Avallone, A., Normanno, N., Pietrantonio, F., Pinto, C., & Ciardiello, F. (2023). Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials. Cancer Medicine, 12(8), 9392–9400. https://doi.org/10.1002/cam4.5699

Chicago

Martini, G., D. Ciardiello, V. Famiglietti, D. Rossini, C. Antoniotti, T. Troiani, S. Napolitano, et al. 2023. “Cetuximab as Third‐line Rechallenge plus Either Irinotecan or Avelumab Is an Effective Treatment in Metastatic Colorectal Cancer Patients with Baseline Plasma RAS/BRAF Wild‐type Circulating Tumor DNA: Individual Patient Data Pooled Analysis of CRICKET and CAVE Trials.” Cancer Medicine 12 (8): 9392–9400. doi:10.1002/cam4.5699.